Lingjun Kong

RNA‐seq Molecular Risk Classification Refines Prognostic Stratification in Childhood B‐Cell Acute Lymphoblastic Leukemia Treated With the CCCG‐ALL‐2020 Protocol: A Real‐World Cohort Study

Clinical risk group and early minimal residual disease (MRD) guide therapy for childhood B‐cell acute lymphoblastic leukemia (B‐ALL) but may not capture all molecular heterogeneity. We evaluated whether RNA sequencing (RNA‐seq) molecular risk classification improved outcome prediction under Chinese Children's Cancer Group (CCCG)‐acute lymphoblastic leukemia (ALL)‐2020.